Session Information
AABB Annual Meeting and CTTXPO 2010
Click here to go to the previous page
What is New and What Has Changed ASFA/AABB Joint Program 
Track
:
TC- Technical/Clinical
Program Code:
9121-TC
Date:
Saturday, October 9, 2010
Time:
2:00 PM to 3:30 PM
EST
Location:
339/340
DIRECTOR
:
Jeffrey Winters, MD, Director Therapeutic Apheresis Unit/Transfusion Medicine Fellowship Program, Mayo Clinic-Rochester
MODERATOR
:
Jeffrey Winters, MD, Director Therapeutic Apheresis Unit/Transfusion Medicine Fellowship Program, Mayo Clinic-Rochester
SPEAKER
(S):
Dr. Zbigniew Szczepiorkowski, MD, PhD, FCAP, Medical Director, Transfusion Medicine Service, Dartmouth-Hitchcock Medical Center
Dr. Beth Shaz, MD, Chief Medical Officer, New York Blood Center
Jeffrey Winters, MD, Director Therapeutic Apheresis Unit/Transfusion Medicine Fellowship Program, Mayo Clinic-Rochester
Description
The American Society for Apheresis (ASFA) categorizes diseases treated by apheresis, based upon a review of the published medical literature, into indication categories to provide those practicing apheresis medicine with guidance on the appropriate apheresis therapy. The categorization in the 2010 Special Edition of the Journal of Clinical Apheresis incorporates many new changes designed to provide the apheresis practitioner even more guidance. In the newest categorizations, the category definitions have changed and a recommendation grade has been incorporated. In addition, the categorization of many diseases has changed based upon the latest available literature and new diseases not previously categorized have now been included. This session will review these changes and provide the attendee with practical knowledge on how to use the newest categorization and recommendation grade.
LEARNER OUTCOMES:
- Discuss changes in categorization of diseases that had previously been categorized, including the rationale behind the re-categorization.
- Discuss the pathophysiology of the disease, the role of apheresis in the treatment, and the evidence supporting the use of apheresis in those diseases that have been categorized for the first time by ASFA.
- Explain the new ASFA recommendation grading scheme and the role this plays in clinical decision making in treating a patient with a therapeutic apheresis procedure.
- Explain the new definitions of the AFSA indications categories and how these can be applied to assist in clinical decision making in treating a patient with a therapeutic apheresis procedure.
| CE Category | CE Value |
|---|---|
| California Clinical Laboratory Personnel | 1.5 |
| California Nurse | 1.8 |
| Florida Laboratory Personnel | 1.8 |
| General Attendee | 1.5 |
| Physician | 1.5 |
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.
This session is a part of:
Online Access
(Code: 9121-TC)
Attendee/Member:$25 USD
Attendee:$40 USD
Member:$40 USD
Non-Attendee/Non-Member $50 USD - Your Price
This session is a part of:
 | Copyright © 2014 by MultiView, Inc. All website graphics, text, design, software, and other works are the copyrighted works of MultiView, Inc. All audio, video, presentation materials, logos and text are the copyrighted works of their respective owners. All Rights Reserved. Any redistribution or reproduction of any materials herein is strictly prohibited. |  |